A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1).

Trial Profile

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1).

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Tivozanib (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms TIVO-1
  • Sponsors AVEO Oncology
  • Most Recent Events

    • 15 Nov 2017 According to an AVEO Oncology media release, company plans to file for FDA approval, once results from Tivo-3 trial are available.
    • 05 Oct 2017 According to an Aveo Oncology media release, the results from TIVO-3 and the TIVO-1 trial will support regulatory approval of tivozanib in the U.S. as a first and third line treatment for RCC
    • 28 Aug 2017 Results published in an AVEO Oncology Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top